ii SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, or Exchange Act. We have based these forward-looking statements largely on our current expectations about future events. Forward-looking statements are not guarantees of future performance or results. Forward- looking statements are based on information available at the time those statements are made and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those in the forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward- looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “intend,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan”, “hope” or the negative of these terms, or similar expressions and comparable terminology intended to identify forward-looking statements. These statements reflect our current views and are based on assumptions and subject to risks and uncertainties, including those set forth in “Part I, Item 1A — Risk Factors.” Forward-looking statements include, but are not limited to, statements about: • the success, cost and timing of our development activities, preclinical studies, clinical trials and regulatory filings; • our ability to obtain funding for our operations, including funding necessary to develop, manufacture and commercialize our product candidates; • the translation of our preclinical results and data and early clinical trial results in particular relating to safety, efficacy and durability into future clinical trials in humans; • the continued durability, efficacy and safety of our product candidates; • our ability to progress each of our product candidates, including tarcocimab, KSI-501 and KSI-101, into later stages of development and towards a Biologics License Application, or BLA; • the scope, progress, results and costs of developing preclinical studies and clinical trials; • the number, size and design of clinical trials that regulatory authorities may require to obtain marketing approval, including the order and number of clinical studies required to support a BLA in retinal vein occlusion, or RVO, diabetic retinopathy, or DR, and wet age-related macular degeneration, or wet AMD, or any of our current or future product candidates; • our and Lonza’s ability to successfully execute on our manufacturing development plan; • our expectations regarding chemistry manufacturing and controls, or CMC, requirements of the United States Food and Drug Administration, or FDA, and other regulatory bodies to support any BLA submission and potential commercial launch; • our expectations regarding enhancements and benefits of new formulations of tarcocimab, KSI-501, KSI-101 or other Antibody Biopolymer Conjugate, or ABC, Platform derived molecules; • the timing or likelihood of regulatory filings and approvals and any related restrictions, limitations and/or warnings in the label of any approved product candidate; • the rate and degree of market acceptance of our product candidates; • the size and growth potential of the markets for our product candidates, if approved for commercial use, and our ability to serve those markets; • the pricing and reimbursement of our product candidates, if approved; • the success of competing products or platform technologies that are or may become available; • our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any product candidates for which we obtain approval; • our expectation as to the concentration of retinal specialists in the United States and its impact on our sales and marketing plans; • uncertainties regarding commercialization of our product candidates; • our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; • the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;